Synopsis
Synopsis
0
KDMF
0
VMF
0
South Africa
Annual Reports
NA
0
Weekly News Recap #Phispers


1. 4-phenylbutyrate
2. 4-phenylbutyric Acid
3. 4-phenylbutyric Acid, Calcium Salt
4. 4-phenylbutyric Acid, Sodium Salt
5. Ammonaps
6. Buphenyl
7. Sodium 4-phenylbutanoate
8. Sodium 4-phenylbutyrate
1. Sodium 4-phenylbutyrate
2. 1716-12-7
3. Sodium 4-phenylbutanoate
4. Buphenyl
5. Tributyrate
6. Ammonaps
7. Benzenebutanoic Acid, Sodium Salt
8. 4-phenylbutyric Acid Sodium Salt
9. Sodium;4-phenylbutanoate
10. 4-phenylbutyric Acid Sodium
11. 4-phenylbutyric Acid, Sodium Salt
12. Acer-001
13. Chebi:75316
14. Nt6k61736t
15. Mfcd00800247
16. Nsc-657802
17. Amx0035 Component Sodium Phenylbutyrate
18. Dsstox_cid_20948
19. Dsstox_rid_79606
20. Dsstox_gsid_40948
21. Pheburane
22. 4pba
23. Sodium Phenylbutyrate [usan]
24. Cas-1716-12-7
25. Ncgc00018113-03
26. Nsc 657802
27. Ammonapse
28. Lunaphen
29. Unii-nt6k61736t
30. Napb
31. Phenylbutyrate Na
32. Sodium Phenylbutyrate [usan:ban]
33. Buphenyl (tn)
34. El-532
35. Vp-101
36. 4-phenylbutyric Acid Sodium 100 Microg/ml In Acetonitrile:water
37. Sodium-4-phenylbutyrate
38. Chembl1746
39. Sodium 4-phenylbutyrate-d11
40. Phenylbutyric Acid Sodium Salt
41. Schembl125792
42. 4-pb
43. Sodium 4-phenylbutyrate, 95%
44. Dtxsid7040948
45. Cmk-304
46. Sodium Phenylbutyrate (jan/usp)
47. Hms2089b22
48. Hms3269n07
49. Hms3413b10
50. Hms3652k18
51. Hms3677b10
52. Hms3885p05
53. Sodium Phenylbutyrate [mi]
54. Sodium Phenylbutyrate [jan]
55. Amy13389
56. Sodium 4-phenylbutyrate;tributyrate
57. Tox21_110826
58. Phenylbutyrate Sodium [vandf]
59. S4125
60. Sodium Phenylbutyrate [mart.]
61. Akos006344763
62. Akos015967141
63. Sodium Phenylbutyrate [usp-rs]
64. Sodium Phenylbutyrate [who-dd]
65. Tox21_110826_1
66. Ccg-213730
67. Ccg-265014
68. Cs-1397
69. Sodium Phenylbutyrate [ema Epar]
70. Sodium Phenylbutyrate, >=98% (hplc)
71. Ncgc00018113-07
72. Ncgc00167830-01
73. As-13914
74. Hy-15654
75. Sy067225
76. Sodium Phenylbutyrate [orange Book]
77. Sodium Phenylbutyrate [ep Monograph]
78. A4107
79. Ft-0619402
80. O0511
81. Sodium Phenylbutyrate [usp Monograph]
82. Sw219199-1
83. D05868
84. F14969
85. Amx-0035 Component Sodium Phenylbutyrate
86. A811337
87. J-010746
88. J-524277
89. Q7553358
90. Sodium Phenylbutyrate, European Pharmacopoeia (ep) Reference Standard
91. Sodium Phenylbutyrate, United States Pharmacopeia (usp) Reference Standard
| Molecular Weight | 186.18 g/mol |
|---|---|
| Molecular Formula | C10H11NaO2 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 4 |
| Exact Mass | 186.06567387 g/mol |
| Monoisotopic Mass | 186.06567387 g/mol |
| Topological Polar Surface Area | 40.1 Ų |
| Heavy Atom Count | 13 |
| Formal Charge | 0 |
| Complexity | 142 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Buphenyl |
| PubMed Health | Sodium Phenylbutyrate (By mouth) |
| Drug Classes | Hyperammonemia Agent, Nutritive Agent |
| Drug Label | BUPHENYL (sodium phenylbutyrate) Tablets for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contain sodium phenylbutyrate. Sodium phenylbutyrate is an off-white crystalline su... |
| Active Ingredient | Sodium phenylbutyrate |
| Dosage Form | Tablet; Powder |
| Route | Oral |
| Strength | 3gm/teaspoonful; 500mg |
| Market Status | Prescription |
| Company | Hyperion Theraps |
| 2 of 4 | |
|---|---|
| Drug Name | Sodium phenylbutyrate |
| PubMed Health | Sodium Phenylbutyrate (By mouth) |
| Drug Classes | Hyperammonemia Agent, Nutritive Agent |
| Drug Label | BUPHENYL (sodium phenylbutyrate) Tablets for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contain sodium phenylbutyrate. Sodium phenylbutyrate is an off-white crystalline su... |
| Active Ingredient | Sodium phenylbutyrate |
| Dosage Form | Tablet; Powder |
| Route | Oral |
| Strength | 500mg; 3gm/teaspoonful |
| Market Status | Prescription |
| Company | Sigmapharm Labs; Ampolgen |
| 3 of 4 | |
|---|---|
| Drug Name | Buphenyl |
| PubMed Health | Sodium Phenylbutyrate (By mouth) |
| Drug Classes | Hyperammonemia Agent, Nutritive Agent |
| Drug Label | BUPHENYL (sodium phenylbutyrate) Tablets for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contain sodium phenylbutyrate. Sodium phenylbutyrate is an off-white crystalline su... |
| Active Ingredient | Sodium phenylbutyrate |
| Dosage Form | Tablet; Powder |
| Route | Oral |
| Strength | 3gm/teaspoonful; 500mg |
| Market Status | Prescription |
| Company | Hyperion Theraps |
| 4 of 4 | |
|---|---|
| Drug Name | Sodium phenylbutyrate |
| PubMed Health | Sodium Phenylbutyrate (By mouth) |
| Drug Classes | Hyperammonemia Agent, Nutritive Agent |
| Drug Label | BUPHENYL (sodium phenylbutyrate) Tablets for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contain sodium phenylbutyrate. Sodium phenylbutyrate is an off-white crystalline su... |
| Active Ingredient | Sodium phenylbutyrate |
| Dosage Form | Tablet; Powder |
| Route | Oral |
| Strength | 500mg; 3gm/teaspoonful |
| Market Status | Prescription |
| Company | Sigmapharm Labs; Ampolgen |
Treatment of chronic management of urea-cycle disorders.
Ammonaps is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or
argininosuccinate synthetase.
It is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease
(partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
A16AX03
A16AX03
A - Alimentary tract and metabolism
A16 - Other alimentary tract and metabolism products
A16A - Other alimentary tract and metabolism products
A16AX - Various alimentary tract and metabolism products
A16AX03 - Sodium phenylbutyrate

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Sodium Phenylbutyrate is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of 2-Hydroxyglutaricaciduria.
Lead Product(s): Sodium Phenylbutyrate,Inapplicable
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Zevra Therapeutics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 15, 2025

Lead Product(s) : Sodium Phenylbutyrate,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Zevra Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Open-Label Study of ACER-001 in Treatment of Combined D,L-2 Hydroxyglutaric Aciduria
Details : Sodium Phenylbutyrate is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of 2-Hydroxyglutaricaciduria.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 15, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Sodium Phenylbutyrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Medium chain acyl CoA dehydrogenase Deficiency.
Lead Product(s): Sodium Phenylbutyrate,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Jerry Vockley
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 14, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Phenylbutyrate,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Jerry Vockley
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sodium Phenylbutyrate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Medium chain acyl CoA dehydrogenase Deficiency.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 14, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Relyvrio (taurursodiol and sodium phenylbutyrate) is a glutamine chelator small molecule drug candidate, being evaluated for the treatment of wolfram syndrome.
Lead Product(s): Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 17, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amylyx Announces Positive Phase 2 Results of AMX0035 For Wolfram Syndrome
Details : Relyvrio (taurursodiol and sodium phenylbutyrate) is a glutamine chelator small molecule drug candidate, being evaluated for the treatment of wolfram syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 17, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Relyvrio (taurursodiol and sodium phenylbutyrate) is a glutamine chelator small molecule drug candidate, being evaluated for the treatment of wolfram syndrome.
Lead Product(s): Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 02, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amylyx Pharmaceuticals Receives Orphan Drug Designation for AMX0035 in Wolfram Syndrome
Details : Relyvrio (taurursodiol and sodium phenylbutyrate) is a glutamine chelator small molecule drug candidate, being evaluated for the treatment of wolfram syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 02, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The net proceeds will be used for launching Olpruva, a new formulation of sodium phenylbutyrate approved as an oral suspension by the FDA, to treat patients with urea cycle disorders.
Lead Product(s): Sodium Phenylbutyrate,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Olpruva
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Perceptive Advisors
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing April 10, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Phenylbutyrate,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Perceptive Advisors
Deal Size : Undisclosed
Deal Type : Financing
Zevra Refinances Debt with Up to $100M in Committed Capital Under New Credit Facility
Details : The net proceeds will be used for launching Olpruva, a new formulation of sodium phenylbutyrate approved as an oral suspension by the FDA, to treat patients with urea cycle disorders.
Product Name : Olpruva
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 10, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Relyvrio (taurursodiol and sodium phenylbutyrate) is an oral small molecule drug candidate under evaluation for treating Wolfram syndrome.
Lead Product(s): Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 10, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amylyx Shares Interim Data from Phase 2 HELIOS Trial On AMX0035
Details : Relyvrio (taurursodiol and sodium phenylbutyrate) is an oral small molecule drug candidate under evaluation for treating Wolfram syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 10, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Relyvrio (sodium phenylbutyrate and taurursodiol) is an oral fixed-dose medication for ALS, with FDA and Health Canada discussions for voluntary discontinuation of marketing authorizations.
Lead Product(s): Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 05, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amylyx to Pull Failed ALS Drug Relyvrio From Market, cut 70% of Staffers
Details : Relyvrio (sodium phenylbutyrate and taurursodiol) is an oral fixed-dose medication for ALS, with FDA and Health Canada discussions for voluntary discontinuation of marketing authorizations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 05, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Relyvrio (sodium phenylbutyrate and taurursodiol) is a specially formulated oral fixed-dose combination, which is being evaluated for the treatment of Amyotrophic Lateral Sclerosis.
Lead Product(s): Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amylyx Reveals Topline Results from Global Phase 3 PHOENIX Trial of AMX0035 in ALS
Details : Relyvrio (sodium phenylbutyrate and taurursodiol) is a specially formulated oral fixed-dose combination, which is being evaluated for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Relyvrio (sodium phenylbutyrate and taurursodiol) is an oral, fixed-dose combination. It is a HDAC inhibitor which is being evaluated in phase 2 clinical trials for the treatment of Wolfram syndrome.
Lead Product(s): Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amylyx Completes Enrollment in HELIOS, Phase 2 Study of AMX0035 for Wolfram Syndrome
Details : Relyvrio (sodium phenylbutyrate and taurursodiol) is an oral, fixed-dose combination. It is a HDAC inhibitor which is being evaluated in phase 2 clinical trials for the treatment of Wolfram syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Amylyx investigational product Relyvrio (sodium phenylbutyrate) with Taurursodiol, is an oral, fixed-dose combination therapy. It is being evaluated in the Phase III clinical trial studies with patient for the treatment of Progressive Supranuclear Palsy.
Lead Product(s): Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 22, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Amylyx investigational product Relyvrio (sodium phenylbutyrate) with Taurursodiol, is an oral, fixed-dose combination therapy. It is being evaluated in the Phase III clinical trial studies with patient for the treatment of Progressive Supranuclear Palsy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 22, 2023

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Application : Controlled & Modified Release
Excipient Details : ACTILLETS are microcrystalline cellulose spheres developed using advanced drug delivery technology to enable effective loading & coating of particles.
Pharmacopoeia Ref : NA
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
84
PharmaCompass offers a list of Sodium Phenylbutyrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sodium Phenylbutyrate manufacturer or Sodium Phenylbutyrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sodium Phenylbutyrate manufacturer or Sodium Phenylbutyrate supplier.
PharmaCompass also assists you with knowing the Sodium Phenylbutyrate API Price utilized in the formulation of products. Sodium Phenylbutyrate API Price is not always fixed or binding as the Sodium Phenylbutyrate Price is obtained through a variety of data sources. The Sodium Phenylbutyrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Sodium 4-Phenylbutyrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sodium 4-Phenylbutyrate, including repackagers and relabelers. The FDA regulates Sodium 4-Phenylbutyrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sodium 4-Phenylbutyrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Sodium 4-Phenylbutyrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Sodium 4-Phenylbutyrate supplier is an individual or a company that provides Sodium 4-Phenylbutyrate active pharmaceutical ingredient (API) or Sodium 4-Phenylbutyrate finished formulations upon request. The Sodium 4-Phenylbutyrate suppliers may include Sodium 4-Phenylbutyrate API manufacturers, exporters, distributors and traders.
click here to find a list of Sodium 4-Phenylbutyrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Sodium 4-Phenylbutyrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Sodium 4-Phenylbutyrate active pharmaceutical ingredient (API) in detail. Different forms of Sodium 4-Phenylbutyrate DMFs exist exist since differing nations have different regulations, such as Sodium 4-Phenylbutyrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Sodium 4-Phenylbutyrate DMF submitted to regulatory agencies in the US is known as a USDMF. Sodium 4-Phenylbutyrate USDMF includes data on Sodium 4-Phenylbutyrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Sodium 4-Phenylbutyrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Sodium 4-Phenylbutyrate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Sodium 4-Phenylbutyrate Drug Master File in Japan (Sodium 4-Phenylbutyrate JDMF) empowers Sodium 4-Phenylbutyrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Sodium 4-Phenylbutyrate JDMF during the approval evaluation for pharmaceutical products. At the time of Sodium 4-Phenylbutyrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Sodium 4-Phenylbutyrate suppliers with JDMF on PharmaCompass.
A Sodium 4-Phenylbutyrate CEP of the European Pharmacopoeia monograph is often referred to as a Sodium 4-Phenylbutyrate Certificate of Suitability (COS). The purpose of a Sodium 4-Phenylbutyrate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Sodium 4-Phenylbutyrate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Sodium 4-Phenylbutyrate to their clients by showing that a Sodium 4-Phenylbutyrate CEP has been issued for it. The manufacturer submits a Sodium 4-Phenylbutyrate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Sodium 4-Phenylbutyrate CEP holder for the record. Additionally, the data presented in the Sodium 4-Phenylbutyrate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Sodium 4-Phenylbutyrate DMF.
A Sodium 4-Phenylbutyrate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Sodium 4-Phenylbutyrate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Sodium 4-Phenylbutyrate suppliers with CEP (COS) on PharmaCompass.
A Sodium 4-Phenylbutyrate written confirmation (Sodium 4-Phenylbutyrate WC) is an official document issued by a regulatory agency to a Sodium 4-Phenylbutyrate manufacturer, verifying that the manufacturing facility of a Sodium 4-Phenylbutyrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Sodium 4-Phenylbutyrate APIs or Sodium 4-Phenylbutyrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Sodium 4-Phenylbutyrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Sodium 4-Phenylbutyrate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Sodium 4-Phenylbutyrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Sodium 4-Phenylbutyrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Sodium 4-Phenylbutyrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Sodium 4-Phenylbutyrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Sodium 4-Phenylbutyrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Sodium 4-Phenylbutyrate suppliers with NDC on PharmaCompass.
Sodium 4-Phenylbutyrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sodium 4-Phenylbutyrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sodium 4-Phenylbutyrate GMP manufacturer or Sodium 4-Phenylbutyrate GMP API supplier for your needs.
A Sodium 4-Phenylbutyrate CoA (Certificate of Analysis) is a formal document that attests to Sodium 4-Phenylbutyrate's compliance with Sodium 4-Phenylbutyrate specifications and serves as a tool for batch-level quality control.
Sodium 4-Phenylbutyrate CoA mostly includes findings from lab analyses of a specific batch. For each Sodium 4-Phenylbutyrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sodium 4-Phenylbutyrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Sodium 4-Phenylbutyrate EP), Sodium 4-Phenylbutyrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sodium 4-Phenylbutyrate USP).